We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Competition from generic drugs allowed European healthcare systems and patients to save more than $100 billion last year, a new report shows. Generics competition nearly doubled access to drugs across seven key therapy areas: angiotensin II antagonists, antiepileptics, antidepressants, antipsychotics, antiulcerants, cholesterol regulators and oral antidiabetics, according to an IMS Institute for Healthcare Informatics report released earlier this month. Read More
Oncology drugmaker Delcath Systems has received orphan drug designation for melphalan to treat intrahepatic cholangiocarcinoma, or ICC, a cancer of the bile duct that arises within the liver. Read More
Insects found in IV solutions have forced Baxter International to voluntarily recall two lots of product, the firm’s seventh recall of an intravenous solution since December 2013. Read More
Venture capitalists invested roughly $2.3 billion in biotechnology companies in the second quarter of 2015, up 32 percent from the prior quarter — the largest quarterly investment in the sector since PwC began issuing its quarterly MoneyTree Report two decades ago. Read More
In its latest study of direct-to-consumer ads, the FDA wants to know if the inclusion of efficacy information in drug advertisements affects how patients perceive the drug. Read More